Twist Bioscience Co. (NASDAQ:TWST) Given Average Rating of “Moderate Buy” by Brokerages

Twist Bioscience Co. (NASDAQ:TWST) has been given an average recommendation of “Moderate Buy” by the ten research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $51.90.

A number of brokerages have issued reports on TWST. Scotiabank upped their price objective on Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 19th. Wolfe Research assumed coverage on Twist Bioscience in a report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. Barclays dropped their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday, November 19th. TD Cowen reissued a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. Finally, Evercore ISI raised their target price on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st.

Twist Bioscience Stock Down 7.8 %

Shares of NASDAQ:TWST opened at $44.61 on Friday. The firm has a fifty day simple moving average of $45.18 and a two-hundred day simple moving average of $46.80. The stock has a market capitalization of $2.65 billion, a P/E ratio of -12.39 and a beta of 1.82. Twist Bioscience has a 52 week low of $27.41 and a 52 week high of $60.90.

Insider Buying and Selling

In other news, CEO Emily M. Leproust sold 1,730 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $46.94, for a total value of $81,206.20. Following the completion of the sale, the chief executive officer now owns 495,523 shares of the company’s stock, valued at approximately $23,259,849.62. This represents a 0.35 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Robert F. Werner sold 1,448 shares of Twist Bioscience stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $64,580.80. Following the transaction, the chief accounting officer now directly owns 45,620 shares in the company, valued at approximately $2,034,652. The trade was a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 101,920 shares of company stock valued at $4,590,734 over the last quarter. 3.92% of the stock is owned by corporate insiders.

Institutional Trading of Twist Bioscience

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Caprock Group LLC lifted its stake in shares of Twist Bioscience by 2.9% during the 2nd quarter. Caprock Group LLC now owns 7,851 shares of the company’s stock worth $387,000 after purchasing an additional 220 shares during the last quarter. Signaturefd LLC raised its holdings in Twist Bioscience by 63.0% in the third quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Twist Bioscience by 1.9% during the second quarter. Arizona State Retirement System now owns 16,187 shares of the company’s stock valued at $798,000 after buying an additional 308 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in shares of Twist Bioscience by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company’s stock valued at $457,000 after buying an additional 312 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Twist Bioscience by 2.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company’s stock worth $734,000 after buying an additional 363 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.